SUBSCRIBE
SUBSCRIBE
News   FDA

Almirall Gets FDA Approval for Migraine Drug

June 3, 2009 | 
1 min read
Reuters -- Spanish pharmaceutical firm Almirall on Wednesday said its Almotriptan migraine drug had gained U.S. Food and Drug Administration approval for adolescents.
FDA Approvals Asia Europe
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Two arrow signs representing the new way and old way approach to business
Regulatory
Atara Climbs Amid Report of FDA Inconsistency Leading to Cell Therapy’s Rejection
February 26, 2026
 · 
1 min read
 · 
Tristan Manalac
Dollar boat swimming on paper waves
Startups
Harbour Cofunds Cancer Startup, Hands Off Clinical-Stage Antibody
February 25, 2026
 · 
2 min read
 · 
Tristan Manalac
Podcast
Lilly Bests Novo Again, Rare Disease Week Goes Regulatory, More CDC Leadership Upheaval
February 25, 2026
 · 
2 min read
 · 
Heather McKenzie
Capitol Hill COVID-19 blood testing, abstract virus testing during pandemic concept, State Building Washington DC, USA, 3d illustration
FDA
Opinion: Balancing Safety Access in Rare Disease—Lessons From Sarepta
February 25, 2026
 · 
6 min read
 · 
Joshua R. Mansbach